by Kelvin Stott | | R&D ROI
Part one of a very insightful analysis by Kelvin Stott showing Pharmaceutical IRR will hit 0% by 2020. Why isn’t translational success rising given better research methodologies and richer datasets? By Kelvin Stott, Director, R&D Portfolio Management, Basel,...
by Kelvin Stott | | Uncategorized
Part 2 of Kelvin Stott’s great work on pharma declining R&D ROI. Why aren’t we finding and drugging new therapeutic targets more efficiently? By Kelvin Stott, Director, R&D Portfolio Management, Basel, Switzerland In Part 1 of this blog, I introduced...
Recent Comments